Category: 41575-94-4

Most of the natural products isolated at present are heterocyclic compounds, so heterocyclic compounds occupy an important position in the research of organic chemistry. A compound: 41575-94-4, is researched, SMILESS is O=C1C2(CCC2)C(O[Pt]O1)=O.N.N, Molecular C6H12N2O4PtJournal, Clinical Trial, Phase II, Article, Randomized Controlled Trial, Breast Cancer Research and Treatment called Updated efficacy of adjuvant epirubicin plus cyclophosphamide followed by taxanes versus carboplatin plus taxanes in early triple-negative breast cancer in phase 2 trial: 8.1-year median follow-up, Author is Zheng, Fangchao; Du, Feng; Wang, Wenmiao; Wang, Yongsheng; Li, Ming; Zhao, Jiuda; Wang, Xue; Yue, Jian; Wang, Jiayu; Yang, Zixuan; Cai, Ruigang; Ma, Fei; Fan, Ying; Li, Qing; Zhang, Pin; Xu, Binghe; Yuan, Peng, the main research direction is BRCA; ECT regimen; SPARC; TP regimen; Triple-negative breast cancer.Reference of cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II).

Abstract: Background: Paclitaxel/docetaxel after doxorubicin plus cyclophosphamide (ECT) is considered as an adjuvant chemotherapy and improves the survival of early triple-neg. breast cancer (TNBC) patients. We aim to assess whether carboplatin plus taxanes (TP) is non-inferior to ECT in prolonging the survival time. Methods: TNBC patients were randomized (1:1) to receive ECT (90 mg/m2 epirubicin + 600 mg/m2 cyclophosphamide followed by 75 mg/m2 docetaxel or 175 mg/m2 paclitaxel every 3 wk, n = 154) or TP (75 mg/m2 docetaxel or 175 mg/m2 paclitaxel + carboplatin AUC 5 every 3 wk, n = 154). These expression of SPARC, PD-L1, and BRCA were studied. Patients were followed up for disease-free survival (DFS), overall survival (OS), and safety. Results: We recruited 308 TNBC patients (median follow-up of 97.6 mo). The median DFS and OS were not reached; the 8-yr DFS rate of ECT and TP arms was 78.4% and 81.7%, resp., while the 8-yr OS rate were 87.2% and 89.1%, resp. In the SPARC (> 50%) subgroup anal., the TP arm had longer DFS (P = 0.049) and a tendency with better OS (P = 0.06) than ECT arm. No significant differences were observed in the DFS and OS between the ECT arm and TP arm in TNBC with SPARC (≤ 50%), PD-L1 (-) PD-L1 (+), and BRCA mutation or BRCA wild (all P values > 0.05). Conclusion: TP showed non-inferiority for DFS and OS compared with ECT in early TNBC. TP may be an effective alternative chemotherapy for TNBC patients whom the standard ECT regimen is not being used. Trail Registration: ClinicalTrials.gov identifier NCT01150513

From this literature《Updated efficacy of adjuvant epirubicin plus cyclophosphamide followed by taxanes versus carboplatin plus taxanes in early triple-negative breast cancer in phase 2 trial: 8.1-year median follow-up》,we know some information about this compound(41575-94-4)Reference of cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II), but this is not all information, there are many literatures related to this compound(41575-94-4).

Reference:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

The reaction of an aromatic heterocycle with a proton is called a protonation. One of articles about this theory is 《A 33-Year-Old Man With Chest Pain.》. Authors are Ballenberger, Matthew; Vojnic, Morana; Indaram, Madhuri; Machnicki, Stephen; Harshan, Manju; Novoselac, Amory V; Singh, Anup; Mina, Bushra.The article about the compound:cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II)cas:41575-94-4,SMILESS:O=C1C2(CCC2)C(O[Pt]O1)=O.N.N).HPLC of Formula: 41575-94-4. Through the article, more information about this compound (cas:41575-94-4) is conveyed.

CASE PRESENTATION: A 33-year-old man was admitted with a 4-week history of intermittent, right-sided chest pain. Two weeks before the incident, he had completed a 10-day course of levofloxacin for a presumed right-sided pneumonia without much improvement. He denied any dyspnea, cough, sputum production, hemoptysis, night sweats, or weight loss. He was an active smoker with a 20-pack-year smoking history and 1-year history of vaping nicotine.

From this literature《A 33-Year-Old Man With Chest Pain.》,we know some information about this compound(41575-94-4)HPLC of Formula: 41575-94-4, but this is not all information, there are many literatures related to this compound(41575-94-4).

Reference:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

Computed Properties of C6H12N2O4Pt. Aromatic heterocyclic compounds can also be classified according to the number of heteroatoms contained in the heterocycle: single heteroatom, two heteroatoms, three heteroatoms and four heteroatoms. Compound: cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II), is researched, Molecular C6H12N2O4Pt, CAS is 41575-94-4, about FRESC: French Real world Extensive stage SCLC Cohorts: A retrospective study on patient characteristics and treatment strategy based on KBP-2010.. Author is Debieuvre, Didier; Dayen, Charles; Dixmier, Adrien; Pau, David; Sibley-Revelat, Anna; Greenwood, William; Gally, Samuel; Falchero, Lionel.

OBJECTIVES: FRESC reanalyzed extensive-stage small-cell lung cancer (ES-SCLC) patient data from the French KBP-2010 cohort to describe the characteristics and therapeutic management of ES-SCLC and provide real-world estimates of survival. METHODS: A target population of first line (1L) ES-SCLC was identified at initial diagnosis in KBP-2010 (KBP population, N = 796). A KBP-2010 subpopulation was defined as patients who also met the IMpower133 clinicaltrial PS ≤ 1 inclusion criteria (KBP-PS_0/1 population, N = 394). Subgroups were defined according to the 1L ES-SCLC chemotherapy regimens: carboplatin or cisplatin with etoposide (Carb-E or Cisp-E subgroups). RESULTS: The vast majority of KBP populations exhibited stage IV ES-SCLC (84.9%) at initial diagnosis. Median age was 66 years; patients were mostly male and smokers. Patients receiving Cisp + Eto were younger (median age 61 years [55.0-67.0]) and fitter (25.5% had PS ≥ 2) than those receiving Carb + Eto (71 years [62.5-77.5]; 44.1%had PS ≥ 2). Median overall survival (OS) of chemotherapy-treated 1L ES-SCLC patients varied from 7.0 months [95% CI, 6.1; 7.8] in the KBPCarb-Esubgroups to 9.6 months [95% CI, 8.4;10.8] in the KBP Cisp-E subgroup. KBP-PS_0/1 population showed better median OS, especially for the Cisp-E subgroup (10 months [95% CI, 8.7; 11.3]). CONCLUSION: In the KBP-PS_0/1 population, median OS was close to the one that was found in the IMpower133 control arm. Although this needs to be confirmed by further research, it suggests the transposability of the IMpower133 results to real-life conditions.

From this literature《FRESC: French Real world Extensive stage SCLC Cohorts: A retrospective study on patient characteristics and treatment strategy based on KBP-2010.》,we know some information about this compound(41575-94-4)Computed Properties of C6H12N2O4Pt, but this is not all information, there are many literatures related to this compound(41575-94-4).

Reference:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

Recommanded Product: 41575-94-4. Aromatic heterocyclic compounds can also be classified according to the number of heteroatoms contained in the heterocycle: single heteroatom, two heteroatoms, three heteroatoms and four heteroatoms. Compound: cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II), is researched, Molecular C6H12N2O4Pt, CAS is 41575-94-4, about Evaluating patient-reported symptoms and late adverse effects following completion of first-line chemotherapy for ovarian cancer using the MOST (Measure of Ovarian Symptoms and Treatment concerns).. Author is Beesley, Vanessa L; Ross, Tanya L; King, Madeleine T; Campbell, Rachel; Nagle, Christina M; Obermair, Andreas; Grant, Peter; DeFazio, Anna; Webb, Penelope M; Friedlander, Michael L; OPAL Study Group.

OBJECTIVES: Knowledge on the course of symptoms patients with ovarian cancer experience is limited. We documented the prevalence and trajectories of symptoms after first-line chemotherapy using the Measure of Ovarian Symptoms and Treatment concerns (MOST). METHODS: A total of 726 patients who received platinum-based chemotherapy for ovarian cancer were asked to complete the MOST every 3 months, beginning 6 months post-diagnosis and continuing for up to 4 years. We used descriptive statistics to examine temporal changes in MOST-S26 index scores for disease or treatment-related (MOST-DorT), neurotoxicity (MOST-NTx), abdominal (MOST-Abdo), and psychological (MOST-Psych) symptoms, and wellbeing (MOST-Wellbeing) and selected individual symptoms. We used group-based trajectory models to identify groups with persistently poor symptoms. RESULTS: The median MOST-Abdo, MOST-DorT and MOST-Wellbeing score were worst at chemotherapy-end but improved and stabilised by 1, 3 and 12 months after treatment, respectively. The median MOST-NTx score peaked at 1 month after treatment before improving, while the median MOST-Psych score did not change substantially over time. Long-term moderate-to-severe fatigue (32%), trouble sleeping (31%), sore hands and feet (21%), pins and needles (20%) and anxiety (18%) were common. Trajectory models revealed groups of patients with persistent symptoms had MOST-DorT scores above 30 and MOST-NTx scores above 40 at treatment-end. CONCLUSIONS: Although many patients report improvements in symptoms by 3 months after first-line chemotherapy for ovarian cancer, patients who score > 30/100 on MOST-S26-DorT or > 40/100 on MOST-S26-NTx at the end of chemotherapy are likely to have persistent symptoms. The MOST could triage this at-risk subset for early intervention.

There is still a lot of research devoted to this compound(SMILES：O=C1C2(CCC2)C(O[Pt]O1)=O.N.N)Recommanded Product: 41575-94-4, and with the development of science, more effects of this compound(41575-94-4) can be discovered.

Reference:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

The reaction of an aromatic heterocycle with a proton is called a protonation. One of articles about this theory is 《High Grade Serous Ovarian Carcinoma in a Liver Transplant Recipient Patient: A Case Report and Review of Literature.》. Authors are Tokalioglu, Abdurrahman Alp; Ozgun, Yigit Mehmet; Celik, Fatih; Akdogan, Meral; Bostanci, Erdal Birol; Turan, Taner; Turkmen, Osman.The article about the compound:cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II)cas:41575-94-4,SMILESS:O=C1C2(CCC2)C(O[Pt]O1)=O.N.N).Category: esters-buliding-blocks. Through the article, more information about this compound (cas:41575-94-4) is conveyed.

According to GLOBOCAN 2020 data, the incidence of ovarian cancer is 1.6%. Ovarian cancer ranks 19th in incidence and 15th in mortality with a rate of 2.1%. High-grade serous ovarian cancer is the most common subtype of malignant ovarian tumors, and around 70% to 80% of all ovarian malignancies are included in this group. The incidence of gynecologic malignancies in liver transplant recipients is between 0% and 1.5%, and the duration of diagnosis for gynecologic cancer after transplantation is between 1 and 59 months. A 52-year-old patient was admitted to our hospital complaining of a periumbilical nodule. Her medical history revealed she had a cadaver liver transplantation in 2003 because of cirrhosis due to hepatitis B. On her physical examination, an erythematous nodular lesion was observed in the umbilical region. Ultrasonography demonstrated diffuse ascites and approximately 30 mm of a soft tissue density with lobulated contours located on the periumbilical skin. Both cytology and biopsy results were reported consistent with high-grade serous ovarian cancer. She underwent an operation, she had no problems during the postoperative follow-ups, and she was discharged on the eighth postoperative day. According to the 2018 International Federation of Gynecology and Obstetrics staging criteria for ovarian cancer, the patient’s cancer was stage IVB. The patient received 6 cycles of adjuvant chemotherapy that included carboplatin (AUC = 6) and paclitaxel (175 mg/m2). The patient was evaluated as having a complete response according to Response Evaluation Criteria in Solid Tumors. The patient has been disease-free for 11 months after diagnosis.

There is still a lot of research devoted to this compound(SMILES：O=C1C2(CCC2)C(O[Pt]O1)=O.N.N)Category: esters-buliding-blocks, and with the development of science, more effects of this compound(41575-94-4) can be discovered.

Reference:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

The three-dimensional configuration of the ester heterocycle is basically the same as that of the carbocycle. Compound: cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II)(SMILESS: O=C1C2(CCC2)C(O[Pt]O1)=O.N.N,cas:41575-94-4) is researched.Synthetic Route of C36H30NO2P. The article 《First-in-human phase 1 study of budigalimab, an anti-PD-1 inhibitor, in patients with non-small cell lung cancer and head and neck squamous cell carcinoma》 in relation to this compound, is published in Cancer Immunology Immunotherapy. Let’s take a look at the latest research on this compound (cas:41575-94-4).

Budigalimab is a humanized, recombinant IgG1 monoclonal antibody targeting programmed cell death protein 1 (PD-1). We present the safety, efficacy, pharmacokinetic (PK), and pharmacodynamic data from patients enrolled in the head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer (NSCLC) expansion cohorts of the phase 1 first-in-human study of budigalimab monotherapy (NCT03000257; registered 15 Dec. 2016). Patients with recurrent/metastatic HNSCC or locally advanced/metastatic NSCLC naive to PD-1/PD-1-ligand inhibitors were enrolled; patients were not selected on the basis of oncogene driver mutations or PD-L1 status. Budigalimab was administered at 250 mg i.v. Q2W or 500 mg i.v. Q4W until disease progression/unacceptable toxicity. The primary endpoints were safety and PK; the secondary endpoint was efficacy. Exploratory endpoints included biomarker assessments. In total, 81 patients were enrolled (HNSCC: N = 41 [PD-L1 pos.: n = 19]; NSCLC: N = 40 [PD-L1 pos.: n = 16]); median treatment duration was 72 days (range, 1-617) and 71 days (range, 1-490) for the HNSCC and NSCLC cohorts, resp. The most frequent grade ≥ 3 treatment-emergent adverse event was anemia (HNSCC: n = 9, 22%; NSCLC: n = 5, 13%). Both dosing regimens had comparable drug exposure and increased interferon gamma-induced chemokines, monokine induced by gamma interferon, and interferon-gamma-inducible protein 10. Objective response rates were 13% (90% CI, 5.1-24.5) in the HNSCC cohort and 19% (90% CI, 9.2-32.6) in the NSCLC cohort. Median progression-free survival was 3.6 mo (95% CI, 1.7-4.7) and 1.9 mo (95% CI, 1.7-3.7) in the HNSCC and NSCLC cohorts. The safety, efficacy and biomarker profiles of budigalimab are similar to other PD-1 inhibitors. Development of budigalimab in combination with novel anticancer agents is ongoing.

There is still a lot of research devoted to this compound(SMILES：O=C1C2(CCC2)C(O[Pt]O1)=O.N.N)Formula: C6H12N2O4Pt, and with the development of science, more effects of this compound(41575-94-4) can be discovered.

Reference:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

In general, if the atoms that make up the ring contain heteroatoms, such rings become heterocycles, and organic compounds containing heterocycles are called heterocyclic compounds. An article called Comparing efficacy and side effects of two systemic chemotherapy regimens for eye-preserving therapy in children with retinoblastoma, published in 2022-02-28, which mentions a compound: 41575-94-4, Name is cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II), Molecular C6H12N2O4Pt, Computed Properties of C6H12N2O4Pt.

Eye-preserving therapy in retinoblastoma comprises systemic chemotherapy, but studies analyzing the efficacy of different chemotherapy regimens are scarce. The efficacy and side effects of two different eye-preserving chemotherapy regimens containing either vincristine, etoposide, and carboplatin (VEC) or cyclophosphamide, vincristine, etoposide, and carboplatin (CyVEC) were compared in a prospective non-interventional observational study including children diagnosed with retinoblastoma between 2013 and 2019 in Germany and Austria. Event-free eye survival (EFES) and overall eye survival (OES) of all 164 eyes treated with both regimens and risk factors were investigated. The EFES after VEC (2-yr EFES 72.3) was higher than after CyVEC (2-yr EFES 50.4) (plogrank < .001). The OES did not differ significantly between the two treatment groups (plogrank = .77; 2-yr OES VEC: 82.1vs. CyVEC: 84.8). Advanced International Classification of Retinoblastoma (ICRB) group was prognostic for a lower EFES (plogrank < .0001; 2-yr EFES ICRB A/B/C 71.3vs. ICRB D/E 43.0) and OES (plogrank < .0001; 2-yr OES ICRB A/B/C 93.1vs. ICRB D/E 61.5). The multivariate anal. showed that age at diagnosis older than 12 mo and ICRB A/B/C were associated with better EFES. No second malignancies or ototoxicities were reported after a follow-up of median 3.1 years after diagnosis of retinoblastoma (range 0.1-6.9 years). Despite omitting cyclophosphamide, the EFES was higher after VEC chemotherapy that contains higher doses of carboplatin compared to CyVEC. The major risk factor for enucleation was advanced ICRB tumor grouping. Randomized clin. trials on efficacy and side effects of eye-preserving chemotherapy are required to tailor treatment protocols for retinoblastoma patients. There is still a lot of research devoted to this compound(SMILES：O=C1C2(CCC2)C(O[Pt]O1)=O.N.N)Computed Properties of C6H12N2O4Pt, and with the development of science, more effects of this compound(41575-94-4) can be discovered.

Reference:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

In general, if the atoms that make up the ring contain heteroatoms, such rings become heterocycles, and organic compounds containing heterocycles are called heterocyclic compounds. An article called DNA-repair status should be assessed in treatment-emergent neuroendocrine prostate cancer before platinum-based therapy, published in 2022-03-01, which mentions a compound: 41575-94-4, Name is cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II), Molecular C6H12N2O4Pt, HPLC of Formula: 41575-94-4.

Objectives : This study sought to provide contemporary data from a multi-institution with respect to DNA-repair genes (DRGs) status and its impact on effects of platinum-based chemotherapy in treatment-emergent neuroendocrine prostate cancer (t-NEPC), for which little data exist. Patients and Methods : All patients were retrospectively collected with eligible biopsied tissues for targeted next generation sequencing (NGS). The main outcomes were radiol. progression-free survival and overall survival according to Response Evaluation Criteria in Solid Tumors, version 1.1. Results : Among the 43 NEPC patients, 13/43 (30%) harbored homozygous deletions, deleterious mutations, or both in DRGs. Eleven patients (11/13, 85%) with DRGs aberrations had effective response, including 7 patients with BRCA1/2 defects and 2 with mismatch repair-deficient caused by MSH2 alterations. While significantly fewer responders (30%) were detected in patients without DRGs aberrations (odds ratio = 12.83, p = 0.003). Compared with patients without genomic DRGs aberrations, the hazard ratio (HR) for radiol. progression in those with DRGs defects was 0.42 (95% confidence interval [CI]: 0.19-0.93), and the HR for death was 0.65 (95% CI: 0.24-1.72). The most common adverse event of Grade 3 or 4 was anemia, as noted in 7 patients (16%). Conclusion : The DRGs status is therapeutically meaningful in t-NEPC. Given the potential responses to platinum-based chemotherapy, our findings support the clin. use of NGS in t-NEPC patients to identify DRGs aberrations.

If you want to learn more about this compound(cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II))HPLC of Formula: 41575-94-4, you may wish to communicate with the author of the article,or consult the relevant literature related to this compound(41575-94-4).

Reference:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

Related Products of 41575-94-4. Aromatic heterocyclic compounds can also be classified according to the number of heteroatoms contained in the heterocycle: single heteroatom, two heteroatoms, three heteroatoms and four heteroatoms. Compound: cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II), is researched, Molecular C6H12N2O4Pt, CAS is 41575-94-4, about Long Non-coding RNAs: Potential Players in Cardiotoxicity Induced by Chemotherapy Drugs. Author is Amrovani, Mehran; Mohammadtaghizadeh, Mohammadjavad; Aghaali, Mahsa Karimzadeh; Zamanifard, Somayeh; Alqasi, Arash; Sanei, Mozhdeh.

One of the most important side effects of chemotherapy is cardiovascular complications, such as cardiotoxicity. Many factors are involved in the pathogenesis of cardiotoxicity; one of the most important of which is long non-coding RNAs (lncRNAs). lncRNA has 200-1000 nucleotides. It is involved in important processes such as cell proliferation, regeneration and apoptosis; today it is used as a prognostic and diagnostic factor. A, various drugs by acting on lncRNAs can affect cells. Therefore, by accurately identifying IncRNAs function, we can play an effective role in preventing the development of cardiotoxicity-induced chemotherapy drugs, and use them as a therapeutic strategy to improve clin. symptoms and increase patient survival.

If you want to learn more about this compound(cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II))Related Products of 41575-94-4, you may wish to communicate with the author of the article,or consult the relevant literature related to this compound(41575-94-4).

Reference:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

The preparation of ester heterocycles mostly uses heteroatoms as nucleophilic sites, which are achieved by intramolecular substitution or addition reactions. Compound: cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II)( cas:41575-94-4 ) is researched.Recommanded Product: 41575-94-4.Alderuccio, Juan Pablo; Kuker, Russ A.; Barreto-Coelho, Priscila; Martinez, Bianca M.; Miao, Feng; Kwon, Deukwoo; Beitinjaneh, Amer; Wang, Trent P.; Reis, Isildinha M.; Lossos, Izidore S.; Moskowitz, Craig H. published the article 《Prognostic value of presalvage metabolic tumor volume in patients with relapsed/refractory diffuse large B-cell lymphoma》 about this compound( cas:41575-94-4 ) in Leukemia & Lymphoma. Keywords: diagnostic agent metabolic tumor volume diffuse large Bcell lymphoma; Diffuse large B-cell lymphoma; metabolic tumor volume; platinum-based chemotherapy. Let’s learn more about this compound (cas:41575-94-4).

Identification of new prognostic factors in relapsed/refractory (rel/ref) diffuse large B-cell lymphoma (DLBCL) is essential for developing risk-adapted approaches. We retrospectively analyzed prognostication based on metabolic tumor volume (MTV) in rel/ref DLBCL (n = 108) before platinum-based salvage chemotherapy. Using 41% SUVmax threshold, patients achieving complete response (CR) exhibited significantly lower baseline values of MTV, compared to those achieving partial response (PR) or with progression of disease (medians MTV 16.26 vs. 72.51 vs. 98.11 mL, resp.). As a continuous variable, log2(MTV) was predictive of failure to achieve CR (1-unit increase odds ratio [OR] = 1.58, p < 0.001). Log2(MTV) significantly predicted progression-free survival (PFS) and overall survival (OS), and one-unit increase in log2(MTV) was associated with shorter PFS (hazard ratio [HR] = 1.12, p = 0.035) and OS (HR = 1.17, p = 0.007). However, heterogeneity in the selection of post-salvage chemotherapy approaches may have affected survival. These data demonstrate the ability of presalvage MTV to discriminate responders from non-responders to platinum-based chemotherapy and predict survival. Here is a brief introduction to this compound(41575-94-4)Recommanded Product: 41575-94-4, if you want to know about other compounds related to this compound(41575-94-4), you can read my other articles.

Reference:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics